By Michael Tetreault, Editor-in-Chief
Today we sit down with the two leaders in the cancer testing, genetics and precision medicine space. Cancer is routinely a concern for Doctors and Patients and preventing, testing and catching it early is so important.
Jo Bhakdi is the founder and CEO of Quantgene. His work in machine learning, sequencing technology, and DNA extraction procedures defines the cutting edge of genomic diagnostics, early disease detection, and precision medicine.
Prior to Quantgene, Jo founded i2X, an investment framework that composes low-risk Venture Capital portfolios across large numbers of technology startups. The i2X platform laid important foundations for advanced analytics in both financial and biotechnology applications, such as the Quantgene machine learning platform.
Bhakdi holds a Masters in Economics and Psychology from Tubingen University, one of Germany’s leading academic institutions, with a focus on financial theory and statistics. He kicked off his career at WPP and Omnicom, where he held Strategy and Executive Director positions.
Beyond his focus on technology and the future of medicine, Bhakdi is dedicated to bringing together the best and brightest and transforming them into pioneers, pushing the boundaries of health, life, and innovation for all.
Meet Dr. Monika E. Hagen, MD, MBA
Monika E. Hagen, MD, MBA is the Chief Medical Officer of Quantgene and a board certified General Surgeon, specializing in bariatric surgery. Trained in Germany, Switzerland, and the United States, she has over a decade of experience as a medical doctor, academic surgeon, teacher, medical device expert, and clinical trial specialist. She also received her MBA from the University of Wales in Cardiff, UK.
Dr. Hagen is an international thought leader and lecturer in bariatric and minimally invasive surgery, as well as surgical robotic technology and its clinical applications. She is a frequent speaker at medical conferences and has published extensively on topics ranging from robotic surgery, to clinical trial design to the future of medicine.
Prior to joining Quantgene and utilizing her clinical, strategic planning, and business development expertise, she has served as a regular consultant to financial, technology, medical, and biotech companies. Dr. Hagen divides her time between professional roles in Geneva, Switzerland, Silicon Valley, and Santa Monica, California.
Resources Discussed In Today’s Interview
For more information, please visit: https://www.quantgene.com/ .
Rachel Strohmeyer and Jo Bhakdi, CEO – firstname.lastname@example.org